Dupixent Lawsuit Lawyer in Alabama | CTCL & T-Cell Lymphoma Claims

Written by Fob James IV, Esq. | Fob James Law Firm, LLC | Last Updated: June 11, 2026

Helping Alabama Patients Harmed by Dupixent (Dupilumab) Pursue Justice and Compensation

If you or a loved one in Alabama was prescribed Dupixent (dupilumab) and later developed cutaneous T-cell lymphoma (CTCL), peripheral T-cell lymphoma (PTCL), mycosis fungoides, or Sézary syndrome, you may have grounds to file a Dupixent lawsuit against the drug’s manufacturers, Sanofi and Regeneron Pharmaceuticals.

At Fob James Law Firm in Birmingham, Alabama, our mass tort attorneys represent clients across all 48 continental states in pharmaceutical injury claims. We have recovered over $100 million for more than 1,000 clients in defective drug and product liability litigation. We handle Dupixent cancer claims on a contingency fee basis — you pay nothing unless we win.

Dupixent Lawsuit Quick Facts

What Is Dupixent, and Why Are Patients Filing Lawsuits?

Dupixent (dupilumab) is an injectable biologic drug manufactured by Sanofi and Regeneron Pharmaceuticals. The FDA approved Dupixent in 2017, and its approved indications have since expanded to include:

• Moderate-to-severe atopic dermatitis (eczema)
• Certain types of asthma
• Chronic rhinosinusitis with nasal polyps
• Eosinophilic esophagitis (EoE)
• Prurigo nodularis
• Chronic obstructive pulmonary disease (COPD)

Dupixent is a blockbuster drug. In 2025, it generated $18.3 billion in global sales — making it one of the highest-grossing pharmaceutical drugs on the market. Sanofi and Regeneron had powerful financial incentives to market Dupixent aggressively. Plaintiffs in Dupixent lawsuits allege this financial pressure contributed to the manufacturers’ failure to disclose a serious cancer risk to patients and prescribers.

The lawsuits center on one core allegation: Sanofi and Regeneron knew or should have known that Dupixent could cause, accelerate, or unmask cutaneous T-cell lymphoma in certain patients — and they failed to warn doctors or patients about this risk. Critically, as of June 2026, the word “lymphoma” does not appear anywhere in Dupixent’s FDA-approved prescribing label.

Does Dupixent Cause Cancer?

Research has linked Dupixent (dupilumab) to a significantly increased risk of cutaneous T-cell lymphoma (CTCL), a rare and aggressive blood cancer that appears on the skin.

Large Database Studies

• JAMA Dermatology (April 2024): Analysis of 19,612 atopic dermatitis patients. Dupixent users showed 4.1x higher odds of developing CTCL (OR 4.1, 95% CI 2.1–8.2) compared to non-users. Risk persisted after adjustment; most diagnoses occurred more than one year after starting Dupixent.
• Dermatologic Therapy (August 2024): TriNetX study of 1.18 million AD patients. Dupixent linked to 4.6x higher relative risk of CTCL (RR 4.6, 95% CI 2.5–8.6). Highest risk in patients over 60 and within the first year of treatment.
• Journal of Allergy and Clinical Immunology (January 2025): FAERS and RNA-Seq analysis showing Dupixent had a 30x higher CTCL reporting rate compared to other medications. Proposed mechanism: IL-13 pathway suppression may accelerate malignant T-cell proliferation.
• European Respiratory Journal (June 2025): Population-based cohort of asthma patients (not atopic dermatitis) found Dupixent users faced 4.5x higher risk of CTCL compared to patients on standard inhaler therapy. This study extends the risk signal beyond eczema patients.

FDA Adverse Event Reporting System (FAERS)

• 2026: The FDA continues reviewing post-marketing CTCL reports but has not issued a recall, and the Dupixent label still carries no CTCL/cancer warning — a central allegation in MDL No. 3180.
• As of October 2025: The FDA’s FAERS database contained nearly 300 lymphoma reports linked to Dupixent, including more than 138 CTCL-specific cases.
• March 2025: The FDA formally announced an investigation into Dupixent’s link to CTCL and placed the drug on a watch list for medications with potentially serious risks. The agency is evaluating whether new cancer warnings should be added to the label.

Case Series and Clinical Reports

Blood Journal (November 2023): 25 patients at Memorial Sloan Kettering Cancer Center. Median time from Dupixent initiation to CTCL diagnosis: 10 months. Disease progression was often accelerated compared to non-Dupixent CTCL cases.

JAAD Case Reports (2022): Seven patients with severe atopic dermatitis developed or experienced worsening CTCL after starting Dupixent. Average time to CTCL diagnosis: 7.8 months. Biopsies showed unmasking of previously hidden lymphoma.

International Journal of Dermatology (2023): Systematic review of 18 cases. All had more than 50% body surface involvement before diagnosis; advanced stages (III/IV) were common. Recommended biopsies 3–4 months post-initiation if no expected improvement.

Cancers Linked to Dupixent: CTCL, PTCL, Mycosis Fungoides, and Sézary Syndrome

Two primary types of T-cell lymphoma have been associated with Dupixent use:

Cutaneous T-Cell Lymphoma (CTCL)

CTCL is a rare form of non-Hodgkin lymphoma involving malignant T-cells that migrate to the skin. In early stages, CTCL can be nearly indistinguishable from eczema or atopic dermatitis — the very condition Dupixent is prescribed to treat. This diagnostic overlap is central to the legal theory in most Dupixent lawsuits. By suppressing skin inflammation, Dupixent may mask the visible signs of an underlying cancer, delaying diagnosis until the disease has progressed to a more advanced, harder-to-treat stage.

The most common forms of CTCL include:

• Mycosis Fungoides — the most prevalent and slow-growing form, presenting as flat, scaly skin patches
• Sézary Syndrome — a more aggressive form that spreads to the blood and lymphatic system, causing widespread redness and immune dysfunction
• Primary cutaneous CD30+ T-cell lymphoproliferative disorders
• Extranodal NK/T-cell lymphoma

Peripheral T-Cell Lymphoma (PTCL)

In addition to CTCL, case reports and emerging litigation have linked Dupixent to peripheral T-cell lymphoma (PTCL) — a broader and often aggressive category of T-cell malignancy. In one reported case (the subject of a 2026 lawsuit filed in Illinois), a patient received only five Dupixent injections before developing swollen lymph nodes and receiving a PTCL diagnosis, requiring chemotherapy and a stem cell transplant. Our firm evaluates both CTCL and PTCL claims for Alabama residents.

Why Dupixent Makes CTCL So Difficult to Diagnose

The most insidious aspect of the Dupixent-CTCL link is the diagnostic gray zone between eczema and early-stage cutaneous T-cell lymphoma. Both conditions present with:

• Red, inflamed, itchy skin patches
• Scaly or crusted plaques
• Lichenification (thickened, leathery skin texture)
• Symptoms that flare and subside over time
• Partial response to topical steroids

Because eczema and early CTCL look nearly identical — even on biopsy in some cases — patients who actually have CTCL are regularly diagnosed with eczema and prescribed Dupixent. When Dupixent suppresses the visible inflammation, the improvement appears to confirm the eczema diagnosis. But if the underlying condition is CTCL, the cancer continues to advance beneath the surface. By the time the true diagnosis is made, patients are often at a more advanced and dangerous stage.

Warning Signs and Symptoms of Dupixent-Associated Lymphoma

If you have taken Dupixent and experience any of the following symptoms, consult your physician immediately. Do not stop or change your Dupixent use without medical guidance — but do request evaluation for lymphoma:

• New or worsening skin patches, plaques, or nodules that are scaly, itchy, or burning
• Persistent red or purple lesions that do not respond to eczema treatments as expected
• Thickened or tumorous skin areas, especially on sun-protected skin surfaces
• Swollen lymph nodes in the neck, armpits, or groin
• Unexplained weight loss, persistent night sweats, or recurring fevers (“B symptoms”)
• Eczema symptoms that initially improve then worsen in an unusual or atypical pattern
• Skin conditions that fail to behave as typical eczema over time

Litigation Updates: Dupixent Lawsuit & Regulatory Timeline

Notable Dupixent Lawsuits

• First wrongful death (Tennessee, October 2025): The first Dupixent wrongful death lawsuit was filed in the Middle District of Tennessee on behalf of a woman who began Dupixent for atopic dermatitis in May 2024, was diagnosed with T-cell lymphoma, and died just months later.
• Georgia filings: Georgia became the most active venue in the litigation, with multiple CTCL cases — including the first Georgia Dupixent lawsuit and a case alleging a woman developed mycosis fungoides after Dupixent use. Georgia held more pending cases than any other district at the time the MDL motion was filed.
• Alabama: Alabama is among the states with a case already pending in the new MDL — meaning the litigation already directly involves Alabama patients.

These cases reflect a consistent pattern: patients with no prior cancer history who developed aggressive T-cell lymphoma after starting Dupixent, and families who allege the manufacturers never warned them.

What Claims Are Brought in a Dupixent Lawsuit?

Dupixent lawsuits filed by patients and families allege that Sanofi and Regeneron:

• Failed to warn patients and prescribers about the risk of CTCL and PTCL, despite available evidence — the primary “failure to warn” theory under Alabama products liability law.
• Marketed Dupixent aggressively to maximize $18+ billion in annual revenue while suppressing or ignoring emerging cancer signals.
• Failed to require prescreening protocols (such as T-cell clonality testing or skin biopsy) in patients with adult-onset or treatment-resistant dermatitis before initiating Dupixent.
• Failed to include any protocol requiring physicians to “stop and investigate” when a patient’s symptoms do not follow the expected eczema progression pattern.
• Failed to update the Dupixent label despite receiving hundreds of adverse event reports to the FDA.
• In wrongful death cases: caused or substantially contributed to the death of patients whose CTCL or PTCL was delayed in diagnosis or accelerated by Dupixent use.

These claims arise primarily under product liability law — specifically failure-to-warn, design defect, and negligence theories — that apply under Alabama law and the laws of other states where clients reside.

Who Can File a Dupixent Lawsuit in Alabama?

You may be eligible to file a Dupixent injury lawsuit in Alabama if you meet the following criteria:

• You were prescribed Dupixent for an approved condition (eczema, asthma, nasal polyps, EoE, COPD, prurigo nodularis, or another indication).
• You were later diagnosed with cutaneous T-cell lymphoma (CTCL), peripheral T-cell lymphoma (PTCL), mycosis fungoides, Sézary syndrome, or another T-cell or NK-cell malignancy.
• Your cancer diagnosis occurred during or after your Dupixent treatment, or your pre-existing lymphoma was allegedly accelerated or unmasked by Dupixent.
• You have medical records — including pathology reports and treatment records — documenting both your Dupixent use and your cancer diagnosis.
• Your claim can be filed within Alabama’s statute of limitations (generally two years from discovery — see below).

Family members of Alabama patients who died from T-cell lymphoma linked to Dupixent may also have standing to file wrongful death claims. Contact our firm immediately to evaluate your specific situation.

What Compensation Can Alabama Dupixent Victims Recover?

Victims of Dupixent-related cancer injuries in Alabama may be entitled to recover:

• Medical expenses — past treatment costs (chemotherapy, radiation, stem cell transplants) and future care costs
• Lost wages and loss of future earning capacity
• Pain and suffering
• Emotional distress and psychological harm
• Loss of enjoyment of life
• Wrongful death damages — for family members of deceased victims, including funeral expenses, loss of consortium, and more

Each case is highly fact-specific. The strength of your medical evidence, the severity of your diagnosis, and the timing of Dupixent use all affect potential recovery. Our attorneys will evaluate your complete medical history during a free case review.

Alabama Statute of Limitations for Dupixent Drug Injury Claims

Under Alabama Code § 6-2-38 and the Alabama Extended Manufacturer’s Liability Doctrine, most defective drug claims must be filed within two years of the date you discovered — or reasonably should have discovered — both the injury (your cancer diagnosis) and its connection to Dupixent.

This discovery rule is critical in Dupixent cases, because many patients did not learn of the alleged Dupixent-CTCL link until 2025 or later, when the FDA announced its formal investigation. If you were diagnosed with CTCL or PTCL years ago but only recently became aware of the Dupixent connection, you may still have time to file.

Do not wait. Statutes of limitations can be complex and are applied strictly in Alabama courts. Read our guide on how long you have to file a personal injury claim in Alabama for more background, or call Fob James Law Firm at 205-407-6009 today for a free case evaluation.

What Should You Do if You Used Dupixent and Developed CTCL?

1. Consult your physician before stopping Dupixent. Do not discontinue your medication without medical supervision.
2. Request a complete copy of your medical records, including dermatology notes, pathology reports, and oncology treatment records.
3. Document your timeline: when you started Dupixent, your dosage and frequency, when symptoms changed, and when you were diagnosed.
4. Preserve all prescription records and pharmacy receipts related to Dupixent.
5. Contact Fob James Law Firm at 205-407-6009 for a free, confidential case evaluation.
6. Do not provide recorded statements to Sanofi, Regeneron, or their insurers without speaking to an attorney first.

Frequently Asked Questions About Dupixent Lawsuits in Alabama

Is there a Dupixent recall in 2026?

No. As of June 2026, the FDA has not recalled Dupixent. The agency formally announced an investigation in March 2025 and continues to monitor adverse event reports of CTCL and other lymphomas. However, Dupixent remains on the market with no cancer warning on its label.

What cancers are linked to Dupixent?

The primary cancers linked to Dupixent are cutaneous T-cell lymphoma (CTCL) — including mycosis fungoides and Sézary syndrome — and peripheral T-cell lymphoma (PTCL). Emerging data also shows elevated risk of other T-cell and NK-cell malignancies.

Is there a Dupixent MDL or class action?

There is now a Dupixent MDL — but it is not a class action. On June 4, 2026, the JPML established MDL No. 3180 in the District of New Jersey before Judge Zahid N. Quraishi, consolidating federal Dupixent CTCL lawsuits for coordinated pretrial proceedings. In an MDL, each plaintiff keeps their own individual case and potential recovery. If you file an Alabama Dupixent claim now, your case can be filed directly into or transferred to MDL No. 3180. Filing early in an MDL is often advantageous.

Can I file a Dupixent lawsuit if I live outside Alabama?

Yes. Fob James Law Firm represents Dupixent clients in 48 states. We are licensed in Alabama, Tennessee, and Georgia, and we co-counsel with qualified attorneys in other jurisdictions where required. Alabama residents always have local counsel available.

How long does a Dupixent lawsuit take?

Mass tort pharmaceutical cases typically take several years from filing to resolution. Now that the MDL is formed (June 2026), bellwether trials and early settlements may occur within 2–3 years of centralization. Filing now rather than waiting preserves your claim and improves your positioning.

What is the statute of limitations for a Dupixent claim in Alabama?

In Alabama, the general statute of limitations for product liability claims is two years from the date you discovered — or reasonably should have discovered — both the injury and its connection to Dupixent. Because many patients only learned of the FDA’s 2025 investigation recently, the clock may have started running in 2025 for some. Contact our firm immediately to determine how the limitation period applies to your specific case.

What does it cost to hire a Dupixent lawyer at Fob James Law Firm?

Nothing upfront. We handle all Dupixent cases on a contingency fee basis. If we do not recover compensation for you, you owe us nothing. There are no out-of-pocket expenses to begin your case.

Is the Dupixent label defective?

Plaintiffs argue yes. As of June 2026, the FDA-approved Dupixent prescribing information does not mention cutaneous T-cell lymphoma, peripheral T-cell lymphoma, mycosis fungoides, Sézary syndrome, or the word “lymphoma” at all — despite hundreds of adverse event reports and multiple peer-reviewed studies establishing a statistical association.

Can the family of someone who died from Dupixent-linked lymphoma file a lawsuit?

Yes. Family members of patients who died from CTCL or PTCL allegedly linked to Dupixent may be able to file a wrongful death lawsuit in Alabama. The first Dupixent wrongful death lawsuit was filed in Tennessee in October 2025. Contact Fob James Law Firm to evaluate your family’s legal options.

I was prescribed Dupixent for asthma, not eczema. Can I still sue?

Potentially yes. A June 2025 study published in the European Respiratory Journal found that Dupixent users with asthma — not atopic dermatitis — faced a 4.5x higher risk of CTCL compared to patients on other asthma medications. The cancer risk signal is not limited to eczema patients.

How do I start a Dupixent claim in Alabama?

Call our Birmingham office at 205-407-6009 or complete our online case evaluation form at callfob.com/contact. Our legal team will review your medical history, explain your rights under Alabama law, and guide you through every step of the process — at no charge until we win.

What is the average Dupixent settlement?

No Dupixent cases have settled or gone to trial yet, so there is no average settlement figure. Now that the cases are consolidated in MDL No. 3180, the litigation will move through discovery, expert (Daubert) rulings, and bellwether trials — the points at which settlement values typically come into focus. Settlement amounts in pharmaceutical cancer cases generally turn on the severity of the diagnosis, the cost of treatment, the strength of the failure-to-warn evidence, and whether the case involves a wrongful death. We provide a free, no-obligation evaluation of your specific case.

Contact an Alabama Dupixent Lawsuit Lawyer Today — Free Consultation

If you or a family member developed T-cell lymphoma, CTCL, PTCL, mycosis fungoides, or Sézary syndrome after taking Dupixent, don’t wait. Every day you delay could affect your statute of limitations and your ability to recover compensation.

Call Fob James Law Firm at 205-407-6009 or complete our online form for a free, confidential case evaluation. We serve clients throughout Alabama, including Birmingham, Montgomery, Mobile, Huntsville, Tuscaloosa, and every surrounding county. We represent clients nationwide in 48 states.

Our Dupixent lawsuit lawyers are ready to fight for your rights and hold Sanofi and Regeneron accountable.